Top 5 Value Stocks To Own For 2018

Envestnet announced Monday that it is spending $195 million to acquire wealth management platform FolioDynamix. The deal will bring Envestnet’s total platform assets to nearly $2 trillion across 10 million investor accounts.

“Acquiring FolioDynamix advances our growth strategy and creates value for our shareholders,” Jud Bergman, chairman and CEO of Envestnet, said in a statement.

He added on a conference call on Monday that this move puts Envestnet on a path to be “the financial wellness network,” connecting enterprises, advisors and clients for the best possible outcomes.

Over the past two years, Envestnet has been developing an open-architecture strategy it calls “Open ENV,” Bergman said, that he believes makes the firm “uniquely positioned” to integrate FolioDynamix’s platform into its own.

“Open ENV creates a quicker path to integration between Envestnet and FolioDynamix, more capabilities [with] the least disruptive approach that enables us to introduce more services and capabilities to our combined base of customers,” he said.

Top 5 Value Stocks To Own For 2018: Cyclacel Pharmaceuticals Inc.(CYCC)

Advisors’ Opinion:

  • [By Alex McGuire]

    As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…

    Pharmaceutical Stock Current Share Price April 2017 Gain
    Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
    Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
    Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
    Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
    Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
    Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
    Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
    Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
    Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
    Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%

    The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

Top 5 Value Stocks To Own For 2018: Netflix, Inc.(NFLX)

Advisors’ Opinion:

  • [By Matt Hogan]

    It has been widely reported that T-Mobile US Inc. (NASDAQ: TMUS) had been in merger talks with Sprint Corp. (NYSE: S), a competitor that is majority owned by Softbank. However, these talks are now on hold as Sprint is negotiating potential deals with two of the largest cable companies in the United States; Comcast Corporation (NASDAQ: CMCSA) and Charter Communications, Inc. (NASDAQ: CHTR). These cable companies are under pressure having lost subscribers due to services like Netflix, Inc. (NASDAQ: NFLX), which recently blew away its second quarter growth estimates.

  • [By Wayne Duggan]

    The same goes for Netflix, Inc. (NASDAQ: NFLX), which currently sports a 333.7 PE ratio. Last quarter Netflix reported its largest quarter of subscriber growth in history, sending the stock higher by 8 percent. The market doesn't seem to care that, based on PE and forward PE, Netflix stock is currently one of the 10 worst values in the entire S&P 500. Forget earnings and share price — Netflix trades almost entirely on subscriber numbers.

  • [By WWW.THESTREET.COM]

    In his “No-Huddle Offense” segment, Cramer said there was no blaming the macro picture during the conference call of Salesforce.com (CRM) , nor Nvidia (NDVA) or Netflix (NFLX) , or even Children’s Place.

  • [By WWW.THESTREET.COM]

    Position: Long GLD small, bonds, SDS; short TLT small, SPY small .

  • [By WWW.THESTREET.COM]

    Apple, Comcast (CMCSA) , Netflix (NFLX) and Alphabet are just some of the tech names in Jim Cramer’s Action Alerts PLUS portfolio. Get his insights on the biggest names in tech here.

  • [By Michael A. Robinson]

    Tech Wealth Gem No. 3
    The First Trust Cloud Computing ETF (Nasdaq: SKYY) is after a massive market. According to Statista.com, cloud computing has grown at a 16% yearly clip in the past five years. And Gartner Group says that $111 billion in tech spending was earmarked for the cloud in 2016 – a number that will hit $216 billion by 2020. Its holdings include Amazon, NetApp Inc. (Nasdaq: NTAP), and Netflix.com Inc. (Nasdaq: NFLX). Trading at just $38, SKYY has a 0.6% expense ratio. Last year, the fund gained nearly 20%; it’s up 7.4% since we first looked at it earlier this year, and it’s averaged profits of 15.4% over the past five years.

Top 5 Value Stocks To Own For 2018: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By David Sterman]

    Growth-oriented investors should also check out Alexion Pharmaceuticals (Nasdaq: ALXN(link is external)), which falls through the cracks between the massive well-established biotechs, and the small-cap biotechs that are still pre-revenue.

    Alexion targets rare and severe diseases, and has built a broad platform of drugs to treat them. Sales growth has never been less than 37% at any point in the past eight years, and 20% to 25% growth appears locked in over coming years as well. Analysts at UBS, who see 30% upside to their $202 price target, believe that a healthy drug pipeline provides multiple catalysts this year in the form of clinical trial updates. They suggest that shares would be worth $230 in a buyout scenario. 

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) soared to the top of the S&P 500 today after its audit committee found no need to restate the company’s financials.

    Agence France-Presse/Getty Images

    Alexion Pharmaceuticalsgained 9.5% to $139.18 today, while the S&P 500 dipped 0.1% to 2,269.00.

    Morgan Stanley’sMatthew Harrison and team argue that the audit committees report is “lifting a cloud” over Alexion, but they still have their concerns:

    Without significant fireworks mgt. has filed the 10-Q lifting a cloud around the details on the potential wrong doing and its impact. While the “pull-in” sales had less than a 1% impact and do not appear pervasive in use as evidenced by the limited amount outside of 4Q15, we do wonder how the increased scrutiny will impact the selling organization and the potential increased conservatism among personnel going forward. We look forward to 2017 guidance and updates to MG filing and 1210 enrollment at the 4Q16 call.

    Alexion’s market capitalization rose to $31.2 billion today from $28.5 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By Johanna Bennett]

    Alexion Pharmaceuticals (ALXN), a drug maker focused on rare diseases, ended Thursday at the top of the list of the best performing stocks in the S&P 500 index.

    The shares climbed almost 3.3%, or $3.78, to close at $118.35, compared to the S&P 500, which fell almost 16 points, or 0.7% to end at 2,328.95.

    Its been a rough two years for Alexion. Since mid-2015, when the stock traded above $200, shares have tumbled on worries about the durability of its main drug Soliris, political furor over high drug prices, and the abrupt departure of two top executives amid an investigation into sales practices.

    The shares are down more than 3% since the start of 2017.

    Solaris sales will be a focus next week when Alexion reports first quarter financial results. Earlier today, Barclays reiterated an overweight rating on the stock and a $115 price target, but raised its 2018 and 2019 earnings estimates, arguing that rivals are unlikely to significantly challenge either Solaris or the experimental drug ALXN1210.

    …we are increasingly comfortable with the Soliris outlook and now forecast 2021E sales at $4.8B vs. our previous $4.6B, which is +5% ahead of consensus. Weve raised 2017 and 2018 adjusted EPS estimates by $0.05 and $0.10 respectively. Our 5-year revenue CAGR increases by +70 bps to 14.7% while EPS growth has improved by +100 bps to 20.0%, near the top of the peer group.

    Barrons weighed in on Alexion in February, which has been bandied about as a takeout candidate. We have argues

    Earlier this week, Credit Suisse analysts listed Alexion as one of three biotech stocks that will steal the spotlight during earnings season.

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) sunk to the bottom of the S&P 500 today, a drop that is being attributed to revelations on Wednesday night that it had to delay its 10-Q because of a whistle blower investigation into its sales practices.

    Getty Images

    Shares of Alexion Pharmaceuticals tumbled 10% to $$113.62 today, while the S&P 500 dipped 0.1% to 2,164.45.

    After speaking with Alexion CEO Vika Sinha, Citigroup’s Robyn Karnauskas and Mohit Bansal see a buying opportunity. “As we highlighted in our previous note, we cannot envision anything that changes numbers fundamentally and see this weakness as buying opportunity,” they write. They also write that they looked at the companies past financials and saw no red flags, while noting that Soliris, the drug that is causing all the problems, “is sold on named patient basis, therefore, chances of fake sales are very minimal.”

    Alexion Pharmaceuticals market capitalization fell to $25.4 billion today from $28.5 billion yesterday.

Top 5 Value Stocks To Own For 2018: Proteon Therapeutics, Inc.(PRTO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Proteon Therapeutics Inc (NASDAQ: PRTO) got a boost, shooting up 31 percent to $1.70 after the company disclosed that it has received the FDA Breakthrough Therapy designation for Vonapanitase. Proteon Therapeutics posted a narrower-than-expected quarterly loss.

Top 5 Value Stocks To Own For 2018: Rayonier Advanced Materials Inc.(RYAM)

Advisors’ Opinion:

  • [By Travis Hoium]

    Shares of materials company Rayonier Advanced Materials Inc (NYSE:RYAM) jumped as much as 11.8% in trading Thursday after announcing a major acquisition. At 3:30 p.m. EDT, the shares were holding at a 10.6% gain on the day.

Leave a Reply

Your email address will not be published. Required fields are marked *